Skip to main content
main-content

05.05.2016 | Interventional | Ausgabe 2/2017

European Radiology 2/2017

Magnetic resonance-guided focused ultrasound treatment of extra-abdominal desmoid tumors: a retrospective multicenter study

Zeitschrift:
European Radiology > Ausgabe 2/2017
Autoren:
Pejman Ghanouni, Andrew Dobrotwir, Alberto Bazzocchi, Matthew Bucknor, Rachelle Bitton, Jarrett Rosenberg, Kristen Telischak, Maurizio Busacca, Stefano Ferrari, Ugo Albisinni, Shannon Walters, Garry Gold, Kristen Ganjoo, Alessandro Napoli, Kim Butts Pauly, Raffi Avedian
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s00330-016-4376-5) contains supplementary material, which is available to authorized users.
Alberto Bazzocchi and Matthew Bucknor contributed equally to this work.

Abstract

Objectives

To assess the feasibility, safety and preliminary efficacy of magnetic resonance-guided focused ultrasound (MRgFUS) for the treatment of extra-abdominal desmoid tumours.

Methods

Fifteen patients with desmoid fibromatosis (six males, nine females; age range, 7–66 years) were treated with MRgFUS, with seven patients requiring multiple treatments (25 total treatments). Changes in viable and total tumour volumes were measured after treatment. Efficacy was evaluated using an exact one-sided Wilcoxon test to determine if the median reduction in viable tumour measured immediately after initial treatment exceeded a threshold of 50 % of the targeted volume. Median decrease after treatment of at least two points in numerical rating scale (NRS) worst and average pain scores was tested with an exact one-sided Wilcoxon test. Adverse events were recorded.

Results

After initial MRgFUS treatment, median viable targeted tumour volume decreased 63 %, significantly beyond our efficacy threshold (P = 0.0013). Median viable total tumour volume decreased (105 mL [interquartile range {IQR}, 217 mL] to 54 mL [IQR, 92 mL]) and pain improved (worst scores, 7.5 ± 1.9 vs 2.7 ± 2.6, P = 0.027; average scores, 6 ± 2.3 vs 1.3 ± 2, P = 0.021). Skin burn was the most common complication.

Conclusions

MRgFUS significantly and durably reduced viable tumour volume and pain in this series of 15 patients with extra-abdominal desmoid fibromatosis.

Key Points

Retrospective four-centre study shows MRgFUS safely and effectively treats extra-abdominal desmoid tumours
This non-invasive procedure can eradicate viable tumour in some cases
Alternatively, MRgFUS can provide durable control of tumour growth through repeated treatments
Compared to surgery or radiation, MRgFUS has relatively mild side effects

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Jetzt e.Med zum Sonderpreis bestellen!

Sichern Sie sich jetzt Ihr e.Med-Abo und sparen Sie 50 %!

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
Fig. 1-S Positioning for MRgFUS ablation of desmoid tumour in the posterior ankle of a 66-year-old man, with additional post-treatment images. This is the same tumour shown in Fig. 1 (patient no. 4). In a, an axial T1-weighted 3D SPGR fat-suppressed image of the ankle used for treatment planning is presented. The white arrow points to the tumour, located between the Achilles tendon (+), and the flexor hallucis longus tendon (*), talus (T) and fibula (F). The patient was in a left lateral decubitus position, with the medial aspect of the ankle located closer to the ultrasound transducer (Tr). Moistened gel pads (GP) are positioned around the ankle, in the near field to allow acoustic coupling to the transducer, and in the far field superficial to the lateral ankle to avoid an air-skin interface, which could otherwise lead to a skin burn. In b, a coronal post-contrast T1-weighted 2D SPGR fat-saturated image obtained 2 weeks before initial treatment shows an enhancing mass in the posterior ankle (white arrow), above the calcaneus (Cal). Sonications were directed from the medial side (M), even though the tumour is closer here to the skin, because the sural nerve traverses the region lateral (L) to the tumour. In c, a coronal post-contrast image obtained 14 months after initial treatment and 5 months after a second treatment, the tumour (white arrow) is predominantly necrotic. Enhancement consistent with residual tumour is present laterally (red asterisk). A curvilinear enhancing line in the medial aspect of the calcaneus represents inflammation related to osteonecrosis from thermal ablation (yellow arrow). In d, a coronal post-contrast image obtained 20 months after initial treatment, the tumour (white arrow) has declined in volume and remains predominantly necrotic. Residual enhancement (red asterisk) is present laterally, but the overall volume of enhancing tumour was unchanged from the prior MR imaging (TIF 7006 kb)
Fig. 2-S MRgFUS treatment of an enlarging, painful desmoid tumour in the right calf in a 15-year-old girl (patient no. 9). She and her family refused surgery and radiation. MRgFUS was used to debulk the portion of the tumour in the superior medial calf, avoiding tumour near the Achilles tendon, and then the remaining tumour was treated with chemotherapy. In a, an axial post-contrast T1-weighted fat-saturated image shows an enhancing infiltrative mass involving the medial gastrocnemius and soleus muscles (white arrow). In b, an axial post-contrast T1-weighted 3D SPGR fat-suppressed image obtained immediately after treatment shows that the majority of the tumour has been ablated (white arrow). Out of 135 mL of tumour volume targeted, 110 mL were non-perfused after treatment (81 %). This represented ablation of 56 % of the total tumour volume (110 of 195 mL). In c, an axial post-contrast T1-weighted fat-saturated image obtained 3 months after MRgFUS ablation and before initiation of chemotherapy shows necrotic tumour with surrounding peripheral enhancement (white arrow), which may represent residual tumour. In d, an axial post-contrast T1-weighted fat-saturated image obtained 7 months after MRgFUS ablation and 4 months after initiation of chemotherapy shows decrease in size of the tumour, and decrease in surrounding peripheral enhancement (white arrow), indicating response to treatment. Total tumour volume decreased at that point from 195 to 156 mL (20 % decline), and viable tumour volume decreased to 118 mL (39 % decline). The patient’s severe pain also improved after MRgFUS treatment (NRS: pre, 9; post, 4) (TIF 11487 kb)
Fig. 3-S MRgFUS treatment of a 14-year-old boy with recurrent, painful desmoid tumour in the right buttock, posterior to the hip joint (patient no. 1). Three years earlier, the patient underwent primary resection of a desmoid tumour in the right popliteal fossa, with recurrence, ultimately leading to above-the-knee amputation. Despite this, there was recurrence in the thigh and buttock, which did not respond to chemotherapy. Tumour in the buttock was targeted for initial MRgFUS treatment, as the tumour was reaching the pelvis, with surgical alternative of hemipelvectomy. In a, an axial post-contrast T1-weighted fat-suppressed image obtained prior to treatment shows bulky tumour (white arrow) posterior to the ischium. In b, an axial post-contrast T1-weighted fat-suppressed image obtained immediately after MRgFUS treatment shows the non-perfused volume of the ablated tumour (white arrow); 74 % (73 of 98 mL) of the tumour was ablated. A small rim of residual enhancement is present laterally; this area was not targeted because of concern for potential damage to cartilage in the hip joint, which was in the far field. In addition, there is a hypoperfused area in the gluteus maximus muscle (between red arrows) that resulted from near-field heating in the muscle. Periosteal hyperemia from far-field heating is also present in the posterior ischium (yellow arrow). In c, an axial post-contrast T1-weighted fat-suppressed image obtained 1 year after treatment shows recurrent tumour (white arrow) posterior to the ischium. The hypoperfused area in the gluteal muscle is smaller (red asterisk), compatible with healing. In d, an axial post-contrast T1-weighted fat suppressed image shows ablation of the recurrent tumour (white arrow). In e, an axial post-contrast T1-weighted fat-suppressed image obtained 23 months after initial treatment, by which time he had received four total treatments to the tumour in his buttock and thigh, shows no solid enhancing component to indicate residual tumour in the buttock at this time (white arrow). Overall, the enhancing volume declined from 98 to 4 cc (96 % decline). The patient’s moderate pain also improved (NRS: pre, 6; post, 0) (TIF 14360 kb)
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 2/2017

European Radiology 2/2017 Zur Ausgabe
  1. Sie können e.Med Radiologie 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.